THE PROGNOSIS
REVISED INTERNATIONAL PROGNOSTIC INDEX
| Stadium | Criteria | Frequency ( %) | 5-year survival (%) |
|---|---|---|---|
| I | ISS I Absence of high-risk cytogenetic abnormality Normal LDH | 28 | 82 |
| II | No stage I or III criteria | 62 | 62 |
| III | ISS III High risk cytogenetic abnormality LDH increased | 10 | 40 |
VALIDATED PROGNOSTIC FACTORS…
- Tumor mass (LDH)
- The beta-2 microglobulin level
- Durie Salmon Stadium
- The proliferation of the tumor clone
- CRP level
- Immunochemical type/severity level: IgG+, IgA++, BJ+++, IgD++++
- The presence of resistant cells
SOME NUMBERS...
GLOBALLY
The prognosis of the disease, which was grim, has improved significantly with the appearance of new targeted therapies. As a result, the median survival was doubled in 20 years, from 3 years to over 6 years.
Obtaining a complete or almost complete response determines the lifespan. Good responses are now obtained in two thirds of the cases compared to one third in the 90s, in particular with the introduction of thalidomide or revlimide and Velcade™ as well as due to the improvement of bone marrow transplants.
THE AVERAGE SURVIVAL...
Age-adjusted standardized net survival (ASNS) at 5 years is 45%
- At stage I > 6 years
- At stage II: 5 years
- At stage III: 3 years
Comments
Post a Comment